Cell
AssigneeAutolus Limited
InventorsSimon Thomas, Martin Pulé, Paul Smith, Isaac Gannon, William Balland
Life of this patent
Estimating the term…
Abstract
The present invention relates to an engineered cell which comprises; (i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (ii) one or more engineered polynucleotides which encode one or more enzymes which are capable of synthesising a therapeutic small molecule when expressed in combination in the cell.
Claims28
An engineered cell which comprises;
- (i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR);
- and
- (ii) one or more engineered polynucleotides which encode one or more enzymes which are capable of synthesising a therapeutic small molecule when expressed in combination in the cell.
(canceled)
-10. (canceled)
(canceled)
(canceled)
A nucleic acid construct which comprises:
- (i) a first nucleic acid sequence which encodes a chimeric antigen receptor (CAR) or a transgenic TCR;
- and
- (ii) one or more nucleic acid sequences which encode one or more enzymes which are capable of synthesising a therapeutic small molecule when expressed in combination in a cell.
(canceled)
A kit of nucleic acid sequences comprising:
- (i) a first nucleic acid sequence which encodes a chimeric antigen receptor (CAR) or a transgenic TCR;
- and
- (ii) one or more nucleic acid sequences which encode one or more enzymes which are capable of synthesising a therapeutic small molecule when expressed in combination in a cell.
A kit of vectors which comprises:
- (i) a first vector which comprises a nucleic acid sequence which encodes a chimeric antigen receptor (CAR) or a transgenic TCR;
- and
- (ii) a second vector which comprises one or more enzymes which are capable of synthesising a therapeutic small molecule when expressed in combination in a cell.
(canceled)
(canceled)
-30. (canceled)
(canceled)
Dependencies are inferred from the claim text.